1. Home
  2. GIGM vs LEXX Comparison

GIGM vs LEXX Comparison

Compare GIGM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GIGM

GigaMedia Limited

N/A

Current Price

$1.40

Market Cap

15.9M

Sector

Technology

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.60

Market Cap

16.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIGM
LEXX
Founded
1998
2004
Country
Taiwan
Canada
Employees
N/A
7
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9M
16.5M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
GIGM
LEXX
Price
$1.40
$0.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
3.4K
81.9K
Earning Date
05-12-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$0.46
52 Week High
$1.89
$1.55

Technical Indicators

Market Signals
Indicator
GIGM
LEXX
Relative Strength Index (RSI) 46.72 40.36
Support Level $1.30 $0.57
Resistance Level $1.49 $0.70
Average True Range (ATR) 0.04 0.05
MACD -0.00 0.00
Stochastic Oscillator 27.27 13.43

Price Performance

Historical Comparison
GIGM
LEXX

About GIGM GigaMedia Limited

GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: